Indrajit Sanyal

Title: Indrajit Sanyal: Innovator in Albumin-Insulin Fusion Proteins

Introduction

Indrajit Sanyal is a notable inventor based in Bethesda, MA, who has made significant contributions to the field of biopharmaceuticals. His work primarily focuses on the development of innovative fusion proteins that enhance insulin activity.

Latest Patents

Sanyal holds a patent for albumin-insulin fusion proteins. This patent discloses fusion proteins that include albumin fused to a polypeptide with insulin activity. The fusion proteins may consist of albumin fused to insulin or an insulin analog. Notably, these fusion proteins can exhibit extended insulin activity in vivo or in vitro compared to insulin that is not fused to albumin. Additionally, the fusion proteins may be formulated as aerosol compositions, providing a novel approach to insulin delivery.

Career Highlights

Indrajit Sanyal is currently employed at Teva Biopharmaceuticals USA, Inc., where he continues to advance his research and development efforts. His work at Teva has positioned him as a key player in the biopharmaceutical industry, particularly in the area of diabetes treatment.

Collaborations

Some of his notable coworkers include Adam C Bell and Craig A Rosen, who contribute to the collaborative environment that fosters innovation at Teva Biopharmaceuticals.

Conclusion

Indrajit Sanyal's innovative work in albumin-insulin fusion proteins represents a significant advancement in diabetes treatment. His contributions to the field highlight the importance of collaboration and research in developing effective biopharmaceutical solutions.